Shares of Regeneron Pharmaceuticals, Inc. REGN have lost 22.6% year to date against the industry’s growth of 0.6%. The stock ...

Regeneron’s shares (currently trading at $552.99) have posted a disappointing 18.9% loss, well below the S&P 500’s 4.5% gain.

Biotech company Regeneron (NASDAQ: REGN) has seen its stock price rally by over 55% this year with the stock currently trading at about $600 per share, due to anticipation surrounding the company ...

Regeneron Pharmaceuticals' (REGN) stock is trading in the red premarket on Thursday after net product sales ... COVID‑19 antibody therapy REGEN-COV saw a decline of -3.52% Y/Y to $613.2M in ...

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

Regeneron (REGN) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2025. ... (REGN) : Free Stock Analysis Report.

Revenue declined 4% from the prior year, as Regeneron struggled to offset the double-digit decline in net product sales, including a 29% plunge in legacy EYLEA, despite a 54% jump in EYLEA HD ...

Regeneron Pharmaceuticals' (REGN 0.38%) sales growth has been lackluster in recent periods. The company is hoping that a higher-dose version of its eye medication Eylea could be a catalyst for ...

A few months back in December 2020, we discussed why Regeneron stock looks undervalued. The stock since then has had a volatile ride with gains of 7% between early December 2020 and late January ...

Regeneron (REGN) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2022. This widely-known consensus outlook gives a ...